Form D · Biotechnology
Abintus Bio, Inc.
San Diego, CA · CIK 0001942876
Offering snapshot reported Aug 16, 2022 · SEC filing
- Reported sold
- $13.7M Offering amount: $15.7M
- Investors reported
- 37 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 16, 2022 | Initial | $13,652,623 | No comparison | 37 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456036
Total amount sold includes amounts paid in cash pursuant to conversion of indebtedness.
Source: Form D, filed Aug 16, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nicholas A. Boyle, Ph.D. | Director, Executive |
| Carlos E. Ibanez | Executive |
| Michael Martin | Director |
| Robert Anthony Williamson | Director |
| Troy Wilson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10355 Science Center Drive, Suite 250
San Diego, CA, 92121
San Diego, CA, 92121